Kahira Pharmaceuticals’ profits fall 39% in 6 months
Kahira Pharmaceuticals and Chemical Industries Company (CPCI) reported a 39% year-on-year decline in net profit after tax for the first half (H1) of fiscal year (FY) 2022/2023, according to the company’s unaudited financial indicators filed to the Egyptian Exchange (EGX).
CPCI’s net profit after tax stood at EGP 50.078 million for the six-month period ended December 31st 2022, compared to profits of EGP 82.057 million in FY H1 2021/2022.
Revenue amounted to EGP 449.077 million in H1 FY 2022/2023, down from EGP 527.104 million in the comparative period a FY earlier.
Kahira Pharmaceuticals is an Egypt-based company involved in the manufacture and trade of pharmaceutical products for human and veterinary use.